These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 18381410)
1. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Kirn DH; Wang Y; Liang W; Contag CH; Thorne SH Cancer Res; 2008 Apr; 68(7):2071-5. PubMed ID: 18381410 [TBL] [Abstract][Full Text] [Related]
2. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Guo ZS; Naik A; O'Malley ME; Popovic P; Demarco R; Hu Y; Yin X; Yang S; Zeh HJ; Moss B; Lotze MT; Bartlett DL Cancer Res; 2005 Nov; 65(21):9991-8. PubMed ID: 16267024 [TBL] [Abstract][Full Text] [Related]
3. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533 [TBL] [Abstract][Full Text] [Related]
4. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Bell E; Shamim M; Whitbeck JC; Sfyroera G; Lambris JD; Isaacs SN Virology; 2004 Aug; 325(2):425-31. PubMed ID: 15246280 [TBL] [Abstract][Full Text] [Related]
11. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Zhang Q; Yu YA; Wang E; Chen N; Danner RL; Munson PJ; Marincola FM; Szalay AA Cancer Res; 2007 Oct; 67(20):10038-46. PubMed ID: 17942938 [TBL] [Abstract][Full Text] [Related]
12. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent. Gentschev I; Stritzker J; Hofmann E; Weibel S; Yu YA; Chen N; Zhang Q; Bullerdiek J; Nolte I; Szalay AA Cancer Gene Ther; 2009 Apr; 16(4):320-8. PubMed ID: 18949014 [TBL] [Abstract][Full Text] [Related]
13. Oncolytic vaccinia virus: from bedside to benchtop and back. Thorne SH Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104 [TBL] [Abstract][Full Text] [Related]
14. Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Huang B; Sikorski R; Kirn DH; Thorne SH Gene Ther; 2011 Feb; 18(2):164-72. PubMed ID: 20739958 [TBL] [Abstract][Full Text] [Related]
15. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615 [TBL] [Abstract][Full Text] [Related]
17. Design and testing of novel oncolytic vaccinia strains. Thorne SH Methods Mol Biol; 2009; 542():635-47. PubMed ID: 19565925 [TBL] [Abstract][Full Text] [Related]
18. Antibody neutralization of the extracellular enveloped form of vaccinia virus. Law M; Smith GL Virology; 2001 Feb; 280(1):132-42. PubMed ID: 11162827 [TBL] [Abstract][Full Text] [Related]
19. The exit of vaccinia virus from infected cells. Smith GL; Law M Virus Res; 2004 Dec; 106(2):189-97. PubMed ID: 15567497 [TBL] [Abstract][Full Text] [Related]
20. Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy. Yun CO Curr Opin Mol Ther; 2008 Aug; 10(4):356-61. PubMed ID: 18683100 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]